Differences between the European and Eurasian Good Pharmacovigilance Practices

Good pharmacovigilance practices (GVP) of the Eurasian Economic Union (EAEU) were prepared based on the GVP of the European Medicines Agency that have been in force in the European Union (EU) since 2012. The EAEU GVP have been in force in the Russian Federation and the other EAEU member states since 2016. It is important to identify potential differences between the current regulations in order to harmonise requirements for the pharmacovigilance systems in the EU and EAEU. The aim of the study was to analyse and compare GVP requirements in the EU and EAEU. The analysis helped to identify differences in the structure and contents of GVP sections, the definitions of terms (EU GVP definitions are more detailed and supported by examples, subsections, and references to other documents). Moreover, supplements and annexes to the EU GVP contain figures, templates, examples, algorithms, and tables, which are missing in the EAEU GVP. Expert analysis of these differences as applied to assessment of the pharmacovigilance systems’ effectiveness, and practical activities of marketing authorisation holders, medicine developers, and regulatory authorities, demonstrated that the two GVPs are sufficiently harmonised and have very few differences. However, the number of differences between the documents increases, as changes are made to the EU GVP. A more comprehensive harmonisation of the EAEU GVP with the current version of the EU GVP will make it possible to develop and use uniform pharmacovigilance documents in the EU and EAEU, and will facilitate the introduction of EAEU medicines into the global pharmaceutical market.

1. Kolbin AS, Zyryanov SK, Belousov DYu. Pharmacovigilance. Moscow: Buki-Vedi: OKI; 2019 (In Russ.)

2. Olefir YuV, Medunitsyn NV, Avdeeva ZhI, Soldatov AA, Movsesyants AA, Merkulov VA, Bondarev VP. Modern biological/biotechnological medicinal products. Topical issues and prospects for development. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIO-preparations. Prevention, Diagnosis, Treatment. 2016;16(2):67–77 (In Russ.)

3. Tsyndymeev AG, Olefir YuV, Merkulov VA, Sakanyan EI. Russian pharmacopoeial practices and the prospects for future development. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(2):4–7 (In Russ.)

4. Gus’kova TA, Khokhlov AL, Romanov BK, Alyautdin RN, Sinitsina OA, Speshilova SA, et al. Safety of drugs: from preclinic to clinic. Moscow–Yaroslavl: Avers-Plus; 2018 (In Russ.)

5. Romanov BK, Toropova II, Kolesnikova EYu. Medication errors. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2014;(2):28–30 (In Russ.)

6. Romanov BK, Zykova NI, Alyautdin RN, Olefir YuV. Identification and evaluation of safety signals of drugs currently under development using a limited data set. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2019;7(4):216–20 (In Russ.)] https://doi.org/10.30895/2312-7821-2019-7-4-216-220

7. Khudoshin AG, Xu X, Romanov BK. Literature monitoring for pharmacovigilance. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2019;7(1):31–43 (In Russ.)] https://doi.org/10.30895/2312-7821-2019-7-1-31-43

8. Krasheninnikov AE, Romanov BK, Safiullin RS. Problem of insufficient involvement of population into pharmacovigilance system. Permskiy meditsinskiy zhurnal = Perm Medical Journal. 2018;35(4):50–5 (In Russ.) https://doi.org/10.17816/pmj35450-55